14/03/2019 19:00:00

Class Action Update KHC, AVEO & CVS Bronstein, Gewirtz & Grossman, LLC

NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

The Kraft Heinz Company (NASDAQ: KHC)

Class Period: May 4, 2017 - February 21, 2019

Deadline: April 25, 2019

For more info:www.bgandg.com/khc

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Kraft’s internal controls, specifically with respect to its procurement area, were inadequate; (2) Kraft would be forced to write down a significant amount of goodwill and certain intangible assets in its Kraft natural cheese business, its Oscar Mayer cold cuts business, and its Canada retail business due to supply chain issues; (3) Kraft failed to advise investors of the foregoing issues; and (4) as a result, Kraft’s public statements were materially false and misleading at all relevant times.

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)

Class Period: August 4, 2016 - January 31, 2019

Deadline: April 26, 2019

For more info:www.bgandg.com/aveo

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in the June 2013; (2) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (3) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (4) as a result, AVEO’s public statements were materially false and misleading at all relevant times. 

CVS Health Corporation (NYSE: CVS)

Class Period: May 21, 2015 - February 20, 2019

Deadline: April 26, 2019

For more info:www.bgandg.com/cvs

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) CVS Health’s financial condition and expected earnings were deteriorating as a result of rising costs and poor results associated with the Omnicare Acquisition; and (2) as a result, CVS Health’s public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

BGG Logo.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 May
DANSKE
Meget interessant refleksion skrevet af Maui. Det kan vores medier godt lære lidt af. Det der kommer..
25
18 May
OMXC25
Et stort flertal af klimaforskerne mener klimaændringerne er menneskeskabte. Dvs. de uddannede perso..
22
15 May
PNDORA
I gaar aftes sad jeg og kiggede lidt naermere paa guidance fra Pandora for FY2019, som de meldte ud ..
22
14 May
E:THIN
Så sidder jeg her og glor på mit depot. Thinfilm falder ekstra meget i øjnene med afkast på minus 96..
20
18 May
VWS
Ditlev.. Havde store ambitioner, og store armbevægelser .. Ikke alt gik godt.. Men finanskrisen kan..
16
18 May
OMXC25
Når man begynder at bruge børn som Greta Thunberg for at fremhæve et budskab ringer advarselsklokker..
16
17 May
VELO
Hej Alle,   Har siddet og kigget på regnskabet, for at finde ud af hvordan 2019 ender. Umiddelbart e..
16
15 May
DANSKE
Apropos skribent 6212.. Og Danske Bank..Ja så må man lade vedkommende at han/hun fik ret. Han anbefa..
16
14 May
DANSKE
Sjovt at der ikke er nogen kritik af SKATs manglende kontrolindsats i forbindelse med momssvindlen, ..
16
18 May
ZEAL
Nedenfor er det samlet udskift af Q1 telefonkonferencen for Zealand Pharma.    Jeg har først trukket..
15

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
2
New Report Shows CRC Screening Rates Increased When a Medically Underserved Population is Offered Epi proColon® Blood Test
3
PRF: Consolidated Unaudited Interim Report of AS PRFoods for 3rd quarter and 9 months of 2018/2019 financial year
4
ESPERITE (ESP) announces listing measure by Euronext due to delay in publication of its 2018 annual report (as announced on 30 April 2019)
5
Eimskip: Letter from Gylfi Sigfússon´s attorney concerning District Prosecutor‘s investigation

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 May 2019 06:26:36
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190514.2 - EUROWEB6 - 2019-05-20 07:26:36 - 2019-05-20 06:26:36 - 1000 - Website: OKAY